DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneMPSvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation Says
The Cure Sanfilippo Foundation is encouraging the U.S. Food & Drug Administration (FDA) to consider Sanfilippo syndrome as a candidate for the agency’s accelerated approval pathway. According to a recent foundation-led study, families of Sanfilippo children are willing to accept modest treatment benefits even if they come with risks.
“Doing nothing is the biggest risk in Sanfilippo!” Glenn O’Neill, foundation president and father to a Sanfilippo child, said in a press release. His statement came at the end of a presentation Oct. 20 at the 13th Annual Rare Disease Scientific Workshop.
The FDA’s Accelerated Approval Program allows for earlier approval of therapies that treat serious conditions and fill an unmet medical need. Sanfilippo syndrome, or mucopolysaccharidosis type III (MPS III), is a rare genetic disorder characterized by the mutations in genes that encode enzymes that break down the complex sugar molecule known as heparan sulfate.
Related Content
-
news & meetingsAVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysacc...AVROBIO, Inc., a leading clinical-stage ...
-
Community CenterRaising an Adult Child With Sanfilippo Syndrome Is TiringI am tired. Caring for my 25-year-old da...
-
educationGene Therapy for Neuronopathic Mucopolysaccharidoses: State of the ArtThe need for long-lasting and transforma...
-
Community CenterMPS 1: Where Are We NowDr. Sandra Kingma from the Centre for Ra...
-
people & placesBeverly L. Davidson, PhDBeverly L. Davidson, PhD, is Director of...
-
Community CenterCure Sanfilippo Foundation – InstagramCure Sanfilippo Foundation is a non prof...
-
news & meetingsDenali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment o...Denali Therapeutics Inc., a biopharmaceu...
send a message
Reset password
password changed successfully!
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email
Want to find the info you need faster?
The symptoms of Mucopolysaccharidosis and the treatments that are available vary depending on which type of Mucopolysaccharidosis a patient has been diagnosed with. Select which type you want to learn more about, and can highlight the resources that are most relevant to your MPS/ML type.
Not now